Genetic testing oversight in the United States has returned to its pre-2024 framework: on September 19, 2025, the FDA reverted 21 CFR 809.3(a) to its prior text, after a federal district court vacated the 2024 laboratory-developed-test rule on March 31, 2025, per the FDA’s policy page. Oversight now rests on CLIA, state law, and FDA review of kits.
What is a laboratory-developed test in the genetic context?
A laboratory-developed test is an in vitro diagnostic designed, manufactured, and run inside a single laboratory that offers it as a service, rather than sold as a kit to other labs. Most clinical sequencing-based genetic tests in the United States, from targeted panels to exome sequencing, have historically been offered as LDTs. MedlinePlus describes the underlying testing plainly: genetic testing looks for changes, sometimes called variants, in DNA, using a sample of blood or tissue; genome sequencing checks all of a person's DNA, while exome sequencing checks only the protein-coding portions.
The distinction between kit and LDT is the load-bearing one in U.S. regulation. A kit sold to many laboratories is a distributed medical device and goes through FDA premarket review. An assay developed and run only inside the laboratory that offers it has, for most of the past half century, been treated differently.
What did the vacated rule actually attempt?
On May 6, 2024, the FDA issued a final rule amending the definition of "in vitro diagnostic products" in 21 CFR 809.3(a) to add the words "including when the manufacturer of these products is a laboratory," per the FDA page. The effect would have been to bring LDTs inside FDA's device regime on a phased schedule, with premarket review, quality system, and reporting requirements applying to tests that had previously operated under enforcement discretion.
That structure did not survive judicial review. On March 31, 2025, a federal district court vacated the final rule in full, and on September 19, 2025 the FDA issued a new final rule reverting to the text of the regulation as it existed before the May 2024 rule's effective date. The reversion is documented on the FDA's Laboratory Developed Tests page, current as of September 19, 2025.
How did the dispute develop over time?
The FDA's own policy page carries the timeline, and it is longer than the 2023-2025 rulemaking cycle suggests:
| Date | Documented step |
|---|---|
| July 19-20, 2010 | Public workshop on oversight of laboratory developed tests |
| January 13, 2017 | FDA discussion paper on LDTs |
| November 16, 2015 | Public health evidence report: 20 case studies on harms from certain LDTs |
| April 19, 2022 | Safety communication on genetic non-invasive prenatal screening tests that may have false results |
| October 3, 2023 | Proposed rule: Medical Devices; Laboratory Developed Tests |
| January 18, 2024 | FDA and CMS joint statement on LDTs |
| May 6, 2024 | Final rule extending device oversight to LDTs |
| March 31, 2025 | Federal district court vacates the final rule |
| September 19, 2025 | Final rule reverting the regulation to its prior text |
The pattern is two decades of discussion, one attempted rule, one vacatur, and a reversion that leaves the underlying policy question where it started.
Who regulates what now?
The operative split, as it stood before 2024 and as it stands again:
| Oversight layer | What it covers | Applies to genetic tests? |
|---|---|---|
| CLIA (CMS) | Laboratory quality, personnel, and analytical validity of testing | Yes, for any clinical laboratory test |
| FDA device review | IVD kits and instruments sold to laboratories | Yes, for distributed products |
| FDA enforcement discretion | LDTs, following the September 2025 reversion | Yes, for tests offered as laboratory services |
| State law | Licensing and, in some states, additional genetic-testing-specific oversight | Varies by state |
CLIA, administered by the Centers for Medicare and Medicaid Services, governs the laboratory as an institution: qualification of personnel, proficiency testing, and the analytical validity of the results a lab reports. It does not evaluate clinical validity, the question of whether a variant interpretation actually predicts disease, and that gap is the one the FDA spent two decades arguing about.
Does that leave a gap for genetics specifically?
The FDA has long argued it does. The agency's policy page links the 2015 report of 20 case studies cataloguing what it described as real and potential harms to patients and public health from certain laboratory developed tests, and the 2022 safety communication on genetic non-invasive prenatal screening tests that may have false results. Those documents are the agency's documented record, not findings about any test currently on the market.
The counter-position, pressed by laboratory organizations throughout the rulemaking, was that CLIA already governs analytical validity and that FDA device review is calibrated to manufactured kits, not to laboratory services that change with the science. The district court's vacatur resolved the legal question of the agency's authority under the device regime, not the policy argument underneath it.
What has and has not changed
Distributed genetic tests, kits, and instruments remain FDA-regulated devices, and clinical laboratories remain subject to CLIA. What changed with the September 2025 reversion is the boundary, not the toolkit on either side of it.
What has not changed is the stakes. Genetic test results drive reproductive decisions, cancer surveillance, and prophylactic treatment choices, and the 2022 prenatal-screening safety communication is a reminder that accuracy problems in this field surface as patient harm, not as abstractions. Whether Congress acts on proposals to codify FDA oversight of LDTs is not yet determined, and no such legislation had been signed into law as of this analysis.
This article is regulatory analysis, not medical advice. It does not evaluate any test or laboratory for any individual. Consult a qualified healthcare professional or genetic counselor about any testing decision.
